Wasif Qureshi

[Jamal Rana, MD @JamalRanaMD]

#ACC25 turned out to be so memorable! A reminder @ACCinTouch is our #professional home. From 75th anniversary Gala about philanthropy, giving back & global health to #scientific sessions filled with learning from peers &teaching FITs #Earlycareers, felt energized for more❤️care.

[American College of Cardiology @ACCinTouch]

South Asian adults have a ⬆️ prevalence of known risk factors for #ASCVD, including hypertension, hyperlipidemia, & diabetes mellitus. The DILWALE Registry adds additional 📊 to help better inform #cvPrev efforts in this population at ⬆️ ASCVD risk. More: https://t.co/BZ0corX0Ke

[Jamal Rana, MD @JamalRanaMD]

Better health straight from the ❤️heart: building healthy habits | KTVU FOX 2 https://t.co/0VsreJTts5

[American College of Cardiology @ACCinTouch]

Top 🔟 Clinical Trials of 2024:

🔥 PREVENT
🔥 DanGer Shock
🔥 REDUCE-AMI
🔥 CLEAR SYNERGY (OASIS 9)
🔥 And more!

Read the details of the clinical trials here: https://t.co/p6WuwqvYz0

[Pooja S. Jagadish, MD @PoojaJagadishMD]

Cardioversion:
🩸If AFib duration ≥48h, either 3 weeks of AC before OR imaging evaluation needed before cardioversion.
🩸Continue AC for at least 4 weeks after cardioversion.
🩸If LAA thrombus is detected, do 3-6 weeks of AC before re-imaging.
#CVBoardPearl #MedX

[Wasif Qureshi @QWasif]

Always on call during the holidays!!

[Jamal Rana, MD @JamalRanaMD]

Had a fun & an important discussion with @HeatherHolmesTV & Alex Savidge @KTVU, about "Holiday ❤️ Syndrome" (#atrialfibrillation) . We enjoy holiday parties due to our friends & loved ones & not necessarily due to #alcohol😊
#moderation
Video Link: https://t.co/BbxpK0KOLO

[JACC Journals @JACCJournals]

#CVCT2024 #JACC: In pts w/ #HFmrEF/#HFpEF, the beneficial effects of #finerenone on clinical events & symptoms were consistent, irrespective of #BMI at baseline, possibly w/ a greater effect on the primary outcome in pts w/ higher BMI. https://t.co/fxZuxXbHt9

#Obesity @mv@mvaduganathan @MkosiborodMD @SubodhVermaMD @scottdsolomon

[American Heart Advocacy @AmHeartAdvocacy]

BREAKING NEWS ‼️❤️ The U.S. Senate voted to unanimously pass the bipartisan HEARTS Act.
Our statement from @Nancyatheart. ⬇️

[American College of Cardiology @ACCinTouch]

A State-of-the-Art review published in #JACCINT provides strategies to address post-#TAVR conduction disturbances and permanent pacemaker implantation.

Read more: https://t.co/YzlOYpwTY8

[The Heart @ZHeart11768530]

🔴Image guided PCI of the coronary arteries⤵️ #2024Review #OpenAccess

The latest evidence that informed the recent guideline recommendations & expand on the specific role of the different imaging modalities before, during, & after PCI https://t.co/lcxv4ixXTZ

[American College of Cardiology @ACCinTouch]

#Diabetes is a major risk factor for #CVD.

Use the #CardioSmart infographic to educate your patients about the link between diabetes and #HeartDisease, along with tips to protect their heart. 🔗 https://t.co/12LGJ7gcrO

#AmericanDiabetesMonth #DiabetesAwareness

[American College of Cardiology @ACCinTouch]

#ACCAdvocacy shares key highlights from the 2025 Medicare #PhysicianFeeSchedule and OPPS Final Rules, both released today. Get the latest on Medicare payment, #telehealth, #QualityPaymentProgram and more. ➡️ https://t.co/ezpb6dC6SC

[Shariq Shamim @ShariqShamimMD]

We discussed this observation on #CardioTwitter: several noted that administering a heparin bolus the ER (100 units/Kg, not max 4,000), rather than waiting until the cath lab, improves TIMI flow by the time the patient reaches the cath lab. This is now supported by an RCT! #TCT2024 @crfheart

[American College of Cardiology @ACCinTouch]

Findings from TAVR UNLOAD show preemptive #TAVR to be safe, but not superior to CASS in patients w/ #HFrEF & moderate AS. While underpowered, researchers did note potential benefits to quality of life w/ preemptive TAVR in select symptomatic patients. https://t.co/TpdFzuHLMW

#JACC #TCT2024 #HeartFailure @JACCJournals

[Davide Capodanno @DFCapodanno]

EARLY TAVR published. Among patients with asymptomatic severe aortic stenosis, a strategy of early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes, driven by the latter. The study's findings may be limited by factors such as its unavoidable unblinded nature, trial-specific vigilance levels, low-risk patient selection, and use of a single valve type. #TCT2024
https://t.co/W1JsvkgrnT

[Pragya Ranjan, MD, FACC @PragyaRanjan]

Thank you! It was such an honor to be a part of this meeting!

[Pragya Ranjan, MD, FACC @PragyaRanjan]

Thank you again for inviting me to be a keynote speaker for the #WIC session at DE ACC by the Sea - it was a fantastic meeting @Hosmane! Such a great discussion with @ErinMichos and @a_l_bailey. Missed my former co-host @CarlyFabrizio! @ACCinTouch

[Pragya Ranjan, MD, FACC @PragyaRanjan]

@DrToniyaSingh